Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Michael Lim; Michael Weller; Ahmed Idbaïh; Joachim P. Steinbach; Gaetano Finocchiaro; Raju R. Raval; George Ansstas; Joachim M. Baehring; Jennie Taylor; Jérôme Honnorat; Kevin Petrecca; Filip De Vos; Antje Wick; Ashley Sumrall; Solmaz Sahebjam; Ingo K. Mellinghoff; Masashi Kinoshita; Mustimbo Roberts; Ruta Slepetis; Deepti Warad; David Leung; Michelle H. Lee; David A. Reardon; Antonio Omuro

doi:10.1093/neuonc/noac116

Abstract

NIVO added to RT + TMZ did not improve survival in patients with newly diagnosed glioblastoma with methylated or indeterminate MGMT promoter. No new safety signals were observed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lim et al. (2022) studied this question.

synapsesocial.com/papers/69dccae2d111c0385b3591a3 https://doi.org/10.1093/neuonc/noac116

View Full Paper

Ask AI

Bookmark

Share

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Abstract

Discussion

Cite This Study

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neuro-Oncology

Keep reading

More related papers

More from Neuro-Oncology